- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Zevalin plus BEAM beats BEAM alone in ASCT
Spectrum Pharmaceuticals is reporting results from a randomized study pitting the company's oncology product Zevalin plus high-dose BEAM chemotherapy (called Z-BEAM) against BEAM chemotherapy alone.
The study was designed to evaluate both the safety and the efficacy of Z-BEAM and an autologous stem cell transplantation in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.
Z-BEAM outperformed BEAM in terms of two-year survival rate, 91% to just 62%.
These results are encouraging, and Spectrum believes that on confirmation of these results, they can receive FDA approval of Zevalin for this indication.